B+
Bull case
25%
Probability
Target price
$35.00
+50.3% vs current
DNLI
Denali TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$23.50
+0.9% vs current
B-
Bear case
25%
Probability
Target price
$11.00
-52.8% vs current
AI sentiment snapshot
Latest data as of 2026-06-10
Recent news sentiment (30D)
-0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+46.1
Score
AI commentary
News tone over the last month is mixed: the AVLAYAH approval/launch was a clear positive, but the May 21 LUMA miss and discontinuation of BIIB122 in idiopathic Parkinson's created a meaningful negative offset. No social-context feed was provided, so the sentiment fields are conservative placeholders rather than a full market-sentiment read.
RankAlpha Sentiment Codex - 2026-06-10
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-13catalystBIIB122/LUMA failure removes the idiopathic Parkinson's programHigh impact
On May 21, Denali and Biogen reported that the Phase 2b LUMA study did not meet primary or secondary endpoints and said BIIB122 in idiopathic Parkinson's disease will be discontinued. This is the key near-term negative overhang and a direct hit to the collaboration thesis.[#SEC-8K-2026-05-21]
2026-06-30eventAVLAYAH U.S. launch is live and first commercial patients are being treatedMedium impact
The May 7 company update said the U.S. commercial launch is underway, first patients have received therapy, distribution and patient-support infrastructure are in place, and major payers have been engaged. That makes launch execution and early uptake the main near-term positive check on the story.[#SEC-8K-2026-05-07]
2026-12-31catalystPlatform readouts from DNL593, DNL628, and DNL126 can re-validate the TransportVehicle storyHigh impact
The May 7 update still points to multiple longer-dated inflection points: DNL593 results by end-2026, first-patient dosing already achieved for DNL628 with 1H 2027 data expected, and a DNL126 confirmatory path in 2027. These are the main longer-horizon catalysts that could offset the Parkinson's setback if execution stays on track.[#SEC-8K-2026-05-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-10 • Updated nightlySource: Internal modelMethodology